Alpine Woods Capital Investors LLC Has $271,000 Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Alpine Woods Capital Investors LLC cut its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 8.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,145 shares of the medical research company’s stock after selling 110 shares during the quarter. Alpine Woods Capital Investors LLC’s holdings in Charles River Laboratories International were worth $271,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Private Advisor Group LLC lifted its stake in Charles River Laboratories International by 15.4% during the first quarter. Private Advisor Group LLC now owns 1,331 shares of the medical research company’s stock worth $378,000 after purchasing an additional 178 shares during the period. Panagora Asset Management Inc. increased its holdings in shares of Charles River Laboratories International by 236.5% in the first quarter. Panagora Asset Management Inc. now owns 2,722 shares of the medical research company’s stock valued at $773,000 after purchasing an additional 1,913 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its holdings in shares of Charles River Laboratories International by 6.6% in the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 6,752 shares of the medical research company’s stock valued at $1,917,000 after purchasing an additional 418 shares in the last quarter. Great West Life Assurance Co. Can increased its holdings in shares of Charles River Laboratories International by 0.4% in the first quarter. Great West Life Assurance Co. Can now owns 25,049 shares of the medical research company’s stock valued at $7,465,000 after purchasing an additional 107 shares in the last quarter. Finally, Raymond James Trust N.A. increased its holdings in shares of Charles River Laboratories International by 33.7% in the first quarter. Raymond James Trust N.A. now owns 1,525 shares of the medical research company’s stock valued at $433,000 after purchasing an additional 384 shares in the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently weighed in on CRL. Evercore ISI raised their price target on shares of Charles River Laboratories International from $260.00 to $265.00 and gave the company an “outperform” rating in a report on Thursday, February 15th. TheStreet raised shares of Charles River Laboratories International from a “c+” rating to a “b-” rating in a report on Friday, March 1st. Argus lifted their target price on shares of Charles River Laboratories International from $240.00 to $290.00 and gave the stock a “buy” rating in a report on Monday, March 18th. UBS Group boosted their price target on shares of Charles River Laboratories International from $270.00 to $290.00 and gave the company a “buy” rating in a report on Thursday, February 15th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Charles River Laboratories International from $270.00 to $280.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. Five equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $253.23.

Charles River Laboratories International Stock Up 1.0 %

NYSE:CRL traded up $2.44 on Friday, hitting $253.10. 529,686 shares of the company’s stock were exchanged, compared to its average volume of 456,211. The firm has a 50-day moving average price of $249.73 and a 200-day moving average price of $218.32. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.52 and a quick ratio of 1.16. Charles River Laboratories International, Inc. has a 52 week low of $161.65 and a 52 week high of $275.00. The company has a market cap of $13.04 billion, a P/E ratio of 27.48, a price-to-earnings-growth ratio of 1.96 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.46 EPS for the quarter, topping the consensus estimate of $2.39 by $0.07. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $991.25 million. During the same period in the previous year, the firm posted $2.98 EPS. The company’s revenue for the quarter was down 7.9% on a year-over-year basis. As a group, analysts expect that Charles River Laboratories International, Inc. will post 11.01 EPS for the current fiscal year.

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Shannon M. Parisotto sold 5,882 shares of the business’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the sale, the executive vice president now directly owns 2,596 shares of the company’s stock, valued at approximately $626,155.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, EVP Shannon M. Parisotto sold 5,882 shares of the company’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $241.20, for a total value of $1,418,738.40. Following the sale, the executive vice president now directly owns 2,596 shares of the company’s stock, valued at approximately $626,155.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP William D. Barbo sold 4,050 shares of the company’s stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the completion of the sale, the vice president now directly owns 22,879 shares in the company, valued at $5,685,431.50. The disclosure for this sale can be found here. Insiders have sold 14,932 shares of company stock valued at $3,693,663 in the last three months. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).